Clinical Trial: RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07006805) titled 'RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis' on April 22.

Brief Summary: RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Relapsing Multiple Sclerosis (RMS) Progressive Multiple Sclerosis (PMS) Multiple Sclerosis - Relapsing Remitting Multiple Sclerosis Multiple Sclerosis (Relapsing Remitting) Multiple Sclerosis (MS) - Relapsing-remitting Progressive Multiple Scleros...